Sutro Biopharma

NASDAQGM:STRO

美國 / 保健 / 生物科技

綜觀

股息

5年歷史財務資料

股價

0.65 USD


Key Metrics	Latest
Total Revenue	62.043 M
Adjusted EBITDA	-231.2 M
EBITDA Margin	-372.7%
Net Profit Margin	-405.0%
Total Assets	387.2 M
Total Debt	23.154 M

5Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	12 Months	Dec-23	Dec-24

Revenue	42.72	61.88	67.77	153.73	62.04	62.04	153.73	62.04
% Growth		0.45	0.10	1.27	(0.60)			(0.60)

Adjusted EBITDA	(66.76)	(93.68)	(123.25)	(82.46)	(231.24)	(231.24)	(82.46)	(231.24)
% Margin	(1.56)	(1.51)	(1.82)	(0.54)	(3.73)	(3.73)	(0.54)	(3.73)

Adjusted EBIT	(71.06)	(98.52)	(128.94)	(89.28)	(238.45)	(238.45)	(89.28)	(238.45)
% Margin	(1.66)	(1.59)	(1.90)	(0.58)	(3.84)	(3.84)	(0.58)	(3.84)

Adjusted Net Income	(62.84)	(102.24)	(131.19)	(114.13)	(251.24)	(251.24)	(114.13)	(251.24)
% Margin	(1.47)	(1.65)	(1.94)	(0.74)	(4.05)	(4.05)	(0.74)	(4.05)

Adjusted Basic EPS	(1.93)	(2.22)	(2.59)	(1.90)	(3.27)	(3.27)	(1.90)	(3.27)

支援算式

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
						Original
USD	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	Dec-24	Dec-23	Dec-24
	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM	YTD-1	YTD

Revenue	43	62	68	154	62	62	154	62
% Growth	NA	44.8%	9.5%	126.8%	-59.6%			-59.6%

Cost of Revenue	(77)	(104)	(10)	(12)	(13)	(13)	(12)	(13)
Gross Profit	(34)	(43)	58	142	50	50	142	50
% Revenue	-80.1%	-68.7%	85.1%	92.3%	79.8%	79.8%	92.3%	79.8%

Research and Development	(77)	(104)	(137)	(180)	(252)	(252)	(180)	(252)
Selling and Marketing	0	0	0	0	0	0	0	0
General and Admin	(37)	(56)	(60)	(63)	(48)	(48)	(63)	(48)
Other Inc / (Exp)	117	100	26	22	40	40	22	40
Total Operating Exp	4	(60)	(170)	(221)	(261)	(261)	(221)	(261)

Operating Income	(31)	(103)	(113)	(79)	(211)	(211)	(79)	(211)
% Revenue	-71.9%	-166.3%	-166.4%	-51.6%	-340.7%	-340.7%	-51.6%	-340.7%

Interest Expense	(1)	(3)	(4)	(9)	(14)	(14)	(9)	(14)
Pre-tax Income	(32)	(106)	(117)	(89)	(225)	(225)	(89)	(225)
Earnings of Discontinued Ops.	0	0	0	0	0	0	0	0
Provision for Taxes	(0)	0	(3)	(18)	(2)	(2)	(18)	(2)
Net Income to Company	(32)	(106)	(119)	(107)	(227)	(227)	(107)	(227)
% Margin	-75.2%	-170.6%	-175.9%	-69.5%	-366.6%	-366.6%	-69.5%	-366.6%

Minority Interest in Earnings	0	0	0	0	0	0	0	0
Net Income to Stockholders	(32)	(106)	(119)	(107)	(227)	(227)	(107)	(227)

Preferred Dividends	0	0	0	0	0	0	0	0
Other Adj.	0	0	0	0	0	0	0	0

Net Income to Common	(32)	(106)	(119)	(107)	(227)	(227)	(107)	(227)
% Margin	-75.2%	-170.6%	-175.9%	-69.5%	-366.6%	-366.6%	-69.5%	-366.6%

As Reported
Basic EPS (Continuing Ops)	(0.99)	(2.29)	(2.35)	(1.78)	(2.96)	(2.96)	(1.78)	(2.96)
Diluted EPS (Continuing Ops)	(0.99)	(2.29)	(2.35)	(1.78)	(2.96)	(2.96)	(1.78)	(2.96)

WA Basic Shares Out.	32.57	46.12	50.74	60.16	76.83	76.83	60.16	76.83
WA Diluted Shares Out.	32.57	46.12	50.74	60.16	76.83	76.83	60.16	76.83

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	(32)	(106)	(117)	(89)	(225)	(225)	(89)	(225)
Addback: Net Interest Expense	1	3	4	9	14	14	9	14
Addback: Other Non Operating Expenses, Total	1	(0)	0	0	5	5	0	5
Addback: Depreciation & Amortization	4	5	6	7	7	7	7	7
Addback: Restructuring Charges	0	0	0	0	0	0	0	0
Addback: Merger / Acquisition Expenses	0	0	0	0	0	0	0	0
Addback: Goodwill Impairment	0	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Invest.	(41)	4	(16)	(10)	(32)	(32)	(10)	(32)
Addback: Gain (Loss) On Sale Of Assets	0	0	0	0	0	0	0	0
Addback: Asset Writedown	0	0	0	0	0	0	0	0
Addback: In Process R&D Expenses	0	0	0	0	0	0	0	0
Addback: Insurance Settlements	0	0	0	0	0	0	0	0
Addback: Legal Settlements	0	0	0	0	0	0	0	0
Addback: Other Unusual Items	0	0	0	0	0	0	0	0
Adjusted EBITDA	(67)	(94)	(123)	(82)	(231)	(231)	(82)	(231)
% Margin	-156.3%	-151.4%	-181.9%	-53.6%	-372.7%	-372.7%	-53.6%	-372.7%

Adjusted EBIT	(71)	(99)	(129)	(89)	(238)	(238)	(89)	(238)
% Margin	-166.3%	-159.2%	-190.3%	-58.1%	-384.3%	-384.3%	-58.1%	-384.3%

Adjusted Net Income Reconciliation
Net Income to Company	(32)	(106)	(119)	(107)	(227)	(227)	(107)	(227)
Addback: Unusual Items	(41)	4	(16)	(10)	(32)	(32)	(10)	(32)
Less: Tax Benefit of Unusual Items (26%)	11	(1)	4	3	8	8	3	8
Adjusted Net Income	(63)	(102)	(131)	(114)	(251)	(251)	(114)	(251)
% Margin	-147.1%	-165.2%	-193.6%	-74.2%	-405.0%	-405.0%	-74.2%	-405.0%

載入錯誤

Sutro Biopharma

NASDAQGM:STRO

美國 / 保健 / 生物科技

5年歷史財務資料